Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences
January 06, 2021 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
November 09, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
44.0% objective response rate and 10.3-month median progression-free survival observed in non-small cell lung cancer (NSCLC) cohortPhase 3 registration-enabling trial planned in first-line metastatic...
Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
November 04, 2020 16:25 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering
September 17, 2020 17:27 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today...
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
September 17, 2020 06:30 ET
|
Checkpoint Therapeutics, Inc
51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohortInterim results presented at ESMO Virtual Congress 2020On track to report full top-line results in...
Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences
September 10, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....
Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020
August 17, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....
Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
August 05, 2020 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020
July 27, 2020 07:30 ET
|
Checkpoint Therapeutics, Inc
Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinomaOver 50% of enrollment target achieved; full enrollment expected around...
Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders
May 22, 2020 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will...